journal
MENU ▼
Read by QxMD icon Read
search

Future Oncology

journal
https://www.readbyqxmd.com/read/28183198/doxorubicin-resistant-osteosarcoma-novel-therapeutic-approaches-in-sight
#1
Claudia M Hattinger, Marilù Fanelli, Elisa Tavanti, Serena Vella, Chiara Riganti, Piero Picci, Massimo Serra
No abstract text is available yet for this article.
February 10, 2017: Future Oncology
https://www.readbyqxmd.com/read/28183193/recent-advances-in-clinical-studies-and-the-evolving-role-of-subtyping-for-patients-with-diffuse-large-b-cell-lymphoma
#2
Grzegorz S Nowakowski, Umberto Vitolo
No abstract text is available yet for this article.
February 10, 2017: Future Oncology
https://www.readbyqxmd.com/read/28183191/bladder-cancer-immunotherapy-swinging-for-the-fences
#3
Fouad Aoun, Elie El Rassy, Alexandre Peltier
No abstract text is available yet for this article.
February 10, 2017: Future Oncology
https://www.readbyqxmd.com/read/28183189/what-advances-have-been-made-in-immune-therapy-for-renal-cell-carcinoma
#4
Elena Verzoni, Paolo Grassi, Raffaele Ratta
No abstract text is available yet for this article.
February 10, 2017: Future Oncology
https://www.readbyqxmd.com/read/28152619/a-multinational-report-of-technical-factors-on-stereotactic-body-radiotherapy-for-oligometastases
#5
Kristin J Redmond, Simon S Lo, Roi Dagan, Ian Poon, Matthew C Foote, Darby Erler, Young Lee, Frank Lohr, Tithi Biswas, Umberto Ricardi, Arjun Sahgal
AIM: Oligometastatic cancer is being increasingly managed with aggressive local therapy using stereotactic body radiation therapy (SBRT). However, few guidelines exist. We summarize the results of an international survey reviewing technical factors for extracranial SBRT for oligometastatic disease to guide safe management. MATERIALS & METHODS: Seven high-volume centers contributed. Levels of agreement were categorized as strong (6-7 common responses), moderate (4-5), low (2-3) or no agreement...
February 3, 2017: Future Oncology
https://www.readbyqxmd.com/read/28147707/activity-of-chemokines-in-prostate-and-renal-tumors-and-their-potential-role-as-future-therapeutic-targets
#6
Alessia Cimadamore, Marina Scarpelli, Francesco Piva, Francesco Massari, Silvia Gasparrini, Andrea Doria, Liang Cheng, Antonio Lopez-Beltran, Rodolfo Montironi
Chemokines are a class of low-molecular-weight proteins that induce chemotaxis and are implicated in the modulation of angiogenesis. The imbalance among angiogenic and antiangiogenic chemokines can promote the development of several conditions, including chronic inflammation, dysplastic transformation and cancer. In this review, we describe the activity and clinical significance of chemokines in prostate and renal tumors and provide an update on ongoing studies in this setting.
February 2, 2017: Future Oncology
https://www.readbyqxmd.com/read/28133974/novel-therapeutic-approaches-in-chondrosarcoma
#7
Genovefa Polychronidou, Vasilios Karavasilis, Seth M Pollack, Paul H Huang, Alex Lee, Robin L Jones
Chondrosarcoma is a malignant tumor of bones, characterized by the production of cartilage matrix. Due to lack of effective treatment for advanced disease, the clinical management of chondrosarcomas is exceptionally challenging. Current research focuses on elucidating the molecular events underlying the pathogenesis of this rare bone malignancy, with the goal of developing new molecularly targeted therapies. Signaling pathways suggested to have a role in chondrosarcoma include Hedgehog, Src, PI3k-Akt-mTOR and angiogenesis...
January 30, 2017: Future Oncology
https://www.readbyqxmd.com/read/28125906/difluoromethylornithine-in-cancer-new-advances
#8
George A Alexiou, Georgios D Lianos, Vassileios Ragos, Vasiliki Galani, Athanassios P Kyritsis
Difluoromethylornithine (DFMO; eflornithine) is an irreversible suicide inhibitor of the enzyme ornithine decarboxylase which is involved in polyamine synthesis. Polyamines are important for cell survival, thus DFMO was studied as an anticancer agent and as a chemoprevention agent. DFMO exhibited mainly cytostatic activity and had single agent efficacy as well as activity in combination with other chemotherapeutic drugs for some cancers and leukemias. Herewith, we summarize the current knowledge of the anticancer and chemopreventive properties of DFMO and assess the status of clinical trials...
January 27, 2017: Future Oncology
https://www.readbyqxmd.com/read/28118748/the-future-of-rehabilitation-in-oncology
#9
Jack B Fu, Shinichiro Morishita
No abstract text is available yet for this article.
January 25, 2017: Future Oncology
https://www.readbyqxmd.com/read/28118740/epstein-barr-virus-gene-expression-and-latency-pattern-in-gastric-carcinomas-a-systematic-review
#10
Joana Ribeiro, Cláudia Oliveira, Mariana Malta, Hugo Sousa
METHODS: A systematic review of literature was conducted to identify all published reports regarding the expression of Epstein-Barr Virus (EBV) proteins/transcripts and EBV latency patterns in EBV-associated gastric carcinomas (EBVaGC). RESULTS: The literature search retrieved 247 papers, of which 25 papers matched the inclusion criteria. The analysis reveals that the most frequently expressed EBV latent proteins are EBNA1 (98.1%) and LMP2A (53.8%), while LMP1 and LMP2B are present in only 10% of cases...
January 25, 2017: Future Oncology
https://www.readbyqxmd.com/read/28110557/preparation-and-biological-evaluation-of-99m-tc-hynic-ser-3-d4-peptide-for-targeting-and-imaging-of-non-small-cell-lung-cancer
#11
Mona Haddad Zahmatkesh, Seyed Mohammad Abedi, Seyed Jalal Hosseinimehr
AIM: In this study, radiolabeled D4 peptide conjugate was studied as a radiotracer for imaging of non-small-cell lung cancer with overexpression of EGFR. METHODS: HYNIC-(Ser)3-D4 peptide was labeled with (99m)Tc using tricine as a co-ligand. Cellular specific binding and internalization as well as in vivo tumor targeting were assessed. RESULTS: The in vitro experiments showed good cellular specific binding. Tumor uptake values as %ID/g were 7...
January 23, 2017: Future Oncology
https://www.readbyqxmd.com/read/28110551/primary-tumor-site-and-anti-egfr-monoclonal-antibody-benefit-in-metastatic-colorectal-cancer-a-meta-analysis
#12
Dandan Li, Qiang Fu, Man Li, Jun Li, Can Yin, Jin Zhao, Feng Li
AIM: This meta-analysis aimed to document the impact of primary tumor site on anti-EGFR monoclonal antibody (mAb) benefit in metastatic colorectal cancer. MATERIALS & METHODS: Tumors with metastatic left-sided colorectal cancer (LCC) were compared with tumors with metastatic right-sided colon cancer (RCC) with respect to anti-EGFR mAb objective response rate (ORR), overall survival (OS) and progression-free survival (PFS) benefit. RESULTS: Comparing LCC with RCC, LCC was found to have significantly superior anti-EGFR mAb ORR (p < 0...
January 23, 2017: Future Oncology
https://www.readbyqxmd.com/read/28095720/baseline-chromogranin-a-and-its-dynamics-are-prognostic-markers-in-gastroenteropancreatic-neuroendocrine-tumors
#13
Wojciech Rogowski, Ewa Wachuła, Anna Lewczuk, Agnieszka Kolesińska-Ćwikła, Ewa Iżycka-Świeszewska, Violetta Sulżyc-Bielicka, Jarosław B Ćwikła
AIM: This study assessed whether absolute chromogranin A (CgA) values at various stages of treatment have prognostic value in patients with pancreatic and midgut neuroendocrine tumors, subjected to peptide receptor radionuclide therapy with (90)Y-[DOTA(0), D-Phe(1), Tyr(3)]-octreotate. PATIENTS & METHODS: CgA was determined before peptide receptor radionuclide therapy, 6 weeks, 6, 12, 18 and 24 months after the last dose of (90)Y-[DOTA(0), D-Phe(1), Tyr(3)]-octreotate...
January 18, 2017: Future Oncology
https://www.readbyqxmd.com/read/28095710/the-evolving-role-of-chemotherapy-in-prostate-cancer
#14
Suliman Boulos, Danish Mazhar
Despite extensive clinical research of different chemotherapy agents for more than three decades, the role of chemotherapy in prostate cancer was only established in 2004, after demonstrating a survival benefit with docetaxel in metastatic castration-resistant prostate cancer. 6 years later, second-line chemotherapy using cabazitaxel, after disease progression on docetaxel, demonstrated an additional survival improvement. Recently, docetaxel given alongside standard hormonal therapy in newly diagnosed advanced prostate cancer was found to lead to significantly improved patient outcomes...
January 18, 2017: Future Oncology
https://www.readbyqxmd.com/read/28095701/malignant-bowel-obstruction-in-advanced-ovarian-cancer
#15
Emma Dean, Leila Khoja, Andrew Clamp, Gordon C Jayson, Dilly Goonetilleke, Alicia M Conway, Jurjees Hasan
AIM: Malignant bowel obstruction (MBO) in ovarian cancer is poorly understood. METHODS: This retrospective cohort study analyzed 129 patients with ovarian cancer and MBO. RESULTS: At presentation, 69 (53%) had platinum-resistant, 37 (29%) platinum-sensitive and 23 (18%) chemotherapy-naive disease. In patients receiving chemotherapy following the MBO episode, median overall survival (OS) was 107 days for chemotherapy-naive patients compared with 83 and 86 for platinum-sensitive or platinum-resistant patients (p = 0...
January 18, 2017: Future Oncology
https://www.readbyqxmd.com/read/28092982/second-malignancy-risk-in-prostate-cancer-and-radiotherapy
#16
Tomer Charas, Amandeep Taggar, Michael J Zelefsky
No abstract text is available yet for this article.
January 17, 2017: Future Oncology
https://www.readbyqxmd.com/read/28088872/prognostic-prediction-by-liver-tissue-proteomic-profiling-in-patients-with-colorectal-liver-metastases
#17
Adalgiza Reyes, Josep Marti, Santiago Marfà, Wladimiro Jiménez, Vedrana Reichenbach, Amalia Pelegrina, Constantino Fondevila, Juan Carlos Garcia Valdecasas, Josep Fuster
AIM: To obtain proteomic profiles in patients with colorectal liver metastases (CRLM) and identify the relationship between profiles and the prognosis of CRLM patients. MATERIALS & METHODS: Prognosis prediction (favorable or unfavorable according to Fong's score) by a classification and regression tree algorithm of surface-enhanced laser desorption/ionization TOF-MS proteomic profiles from cryopreserved CRLM (patients) and normal liver tissue (controls). RESULTS: The protein peak 7371 m/z showed the clearest differences between CRLM and control groups (94...
January 16, 2017: Future Oncology
https://www.readbyqxmd.com/read/28088868/prognostic-values-of-ki-67-in-neoadjuvant-setting-for-breast-cancer-a-systematic-review-and-meta-analysis
#18
Lun Li, Dongdong Han, Xiaowei Wang, Quan Wang, Jinhui Tian, Jia Yao, Liqin Yuan, Ke Qian, Qiongyan Zou, Wenjun Yi, Enxiang Zhou, Kehu Yang
AIM: To assess the prognostic values of Ki-67 in neoadjuvant setting for breast cancer patients. METHODS: PubMed and EMBASE were searched. Revman software was used to conduct random-effect model meta-analysis. RESULTS: 49 studies (14,076 patients) were included. High Ki-67 before and after neoadjuvant chemotherapy were associated with worse overall survival (OS; before: hazard ratio [HR]: 2.29; 95% CI: 1.42-3.69; after: HR: 2.24; 95% CI: 1...
January 16, 2017: Future Oncology
https://www.readbyqxmd.com/read/28076966/evesor-a-model-based-multiparameter-phase-i-trial-to-optimize-the-benefit-toxicity-ratio-of-everolimus-and-sorafenib
#19
Mévidette El-Madani, Olivier Colomban, Michel Tod, Denis Maillet, Julien Peron, Claire Rodriguez-Lafrasse, Osama A Badary, Pierre-Jean Valette, Thibaud Lefort, Philippe Cassier, Siham M El-Shenawy, Ebtehal El-Demerdash, Juliette Hommel-Fontaine, Jerome Guitton, Marie-Claude Gagnieu, Bassant Mm Ibrahim, Catherine Barrois, Gilles Freyer, Benoit You
AIM: This novel multiparameter Phase I study aimed to optimize doses/dosing schedules of everolimus and sorafenib drug combination, based on modeling/simulation (NCT01932177). PATIENTS & METHODS: About 26 patients with solid tumors were treated in four different dosing schedules. Everolimus once daily + sorafenib twice daily were given continuously in arms A and B, and intermittently in arms C (alternating every other week) and D (everolimus continuous and sorafenib 3 days on/4 days off)...
January 12, 2017: Future Oncology
https://www.readbyqxmd.com/read/28075171/the-role-of-tumor-microenvironment-in-collective-tumor-cell-invasion
#20
Jia-Shun Wu, Su-Rui Sheng, Xin-Hua Liang, Ya-Ling Tang
For many cancer types, cancer cells invade into surrounding tissues by collective movement of cell groups that remain connected via cell-cell junctions. This migration is completely distinguished from single-cell migration, in which cancer cells disrupt the tight intercellular junctions and gain a mesenchymal phenotype. Recently, emerging evidence has revealed that collective cell invasion depends on not only cell-intrinsic mechanisms but also on extracellular mechanisms by bidirectional interplay between the tumor cell and the tumor environment...
January 11, 2017: Future Oncology
journal
journal
41162
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"